The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | The best of gastric and gastroesophageal junction cancer at ASCO GI 2023
Samuel Klempner, MD, Massachusetts General Hospital, Boston, MA, comments on his highlights in gastric or gastroesophageal junction cancer (GC/GEJC) during the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including findings from the Neo-AEGIS trial (NCT01726452), as well as the SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials, which both assessed zolbetuximab, a novel anti-claudin 18.2 monoclonal antibody. RATIONALE-305 (NCT03777657) and INTEGRATE IIa (NCT02773524) additionally assessed tislelizumab and regorafenib respectively in GC/GEJC. This interview took place at the ASCO) 2023 GI Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
